当前新型治疗时代自体干细胞移植后进展的复发/难治性霍奇金淋巴瘤患者的结局:一项回顾性分析
该回顾性分析纳入87例自体干细胞移植(ASCT)后复发/进展的复发/难治性霍奇金淋巴瘤(RR-HL)患者,评估当前新型治疗时代的结局。接受新型药物(包括维布妥昔单抗)治疗的患者中位总生存(OS)较未接受者显著改善(85.6 vs 17.1个月;P < .001)。研究显示新型治疗显著改善RR-HL患者OS,并为这些药物在当前时代的获益提供「真实世界」证据。
要点
- ASCT后复发/进展的RR-HL患者接受新型药物(含维布妥昔单抗)中位OS为85.6个月,未接受者为17.1个月(P < .001)。
- ASCT后接受放疗者中位OS为34.1个月,未接受者为17.0个月(P = .015)。
- 复发较原发难治疾病中位OS为51.8 vs 25.6个月(P = 0.013);ASCT初始缓解(CR/PR)较SD/PD为46.1 vs 20.4个月(P = .011)。
核心结论
- 当前研究显示接受新型治疗的RR-HL患者OS显著改善,并为这些药物在当前时代改善结局的作用提供「真实世界」证据。
研究设计与样本
- 回顾性分析,纳入87例ASCT后复发的RR-HL患者,评估结局。
主要发现
- 接受新型药物(包括维布妥昔单抗)治疗者较未接受者中位OS显著改善(85.6 vs 17.1个月;P < .001)。
- 单因素分析中,ASCT后接受放疗者较未接受者中位OS改善(34.1 vs 17.0个月;P = .015)。
- 复发较原发难治疾病中位OS改善(51.8 vs 25.6个月;P = 0.013)。
- ASCT初始缓解(CR/PR)较SD/PD中位OS改善(46.1 vs 20.4个月;P = .011)。
- 2010年及以后移植较2010年前移植中位OS改善(未达到 vs 24.5个月;P = .025)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with relapsed/refractory Hodgkin lymphoma (RR-HL) who progress or relapse following autologous stem cell transplantation (ASCT) have historically had a poor prognosis. Several novel agents, particularly brentuximab vedotin, have shown efficacy in this setting. However, there remains a paucity of data characterizing outcomes outside of clinical trials and how these novel agents have impacted prognosis in general population of patients with RR-HL. Here, we conducted a retrospective analysis to evaluate outcomes in 87 patients with RR-HL with relapse post-ASCT. Treatment with novel agents (including brentuximab vedotin) was associated with significant improvement in median overall survival (OS) compared to patients who did not receive novel agents (85.6 vs 17.1 months; P < .001). Additional factors associated with improved OS in univariate analysis include treatment with radiation therapy post-ASCT (34.1 vs 17.0 months; P = .015), chemosensitivity (i.e., relapsed compared to primary refractory disease; 51.8 vs 25.6 months; p = 0.013), initial response to ASCT (i.e., CR/PR compared to SD/PD; 46.1 vs 20.4 months; P = .011), and transplantation in 2010 and later compared to prior to 2010 (not reached vs 24.5 months; P = .025). The current study demonstrates markedly improved OS in RR-HL patients treated with novel therapeutics and lends "real world" credence to the role of these agents in improving outcomes in the current era.
引用
- Bair SM, Strelec L, Nagle SJ, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. Am J Hematol. 2017. PMID: 28512788. doi:10.1002/ajh.24792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。